neurogen

neurogen

[noo͡r′əjən]
Etymology: Gk, neuron + genein, to produce
a substance within the early developing embryo that stimulates the primary organizer to initiate the formation of the neural plate, which gives rise to the primary axis of the body. See also neurotransmitter.
References in periodicals archive ?
13 /PRNewswire-FirstCall/ -- Neurogen Corporation today announced that it has commenced Phase I human testing of the Company's leading drug candidate for treatment of obesity.
Neurogen Corporation (Branford, CT) has consummated its previously announced alliance with Merck & Co.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has completed the acquisition of Neurogen Corporation (NASDAQ: NRGN), following approval of the transaction by Neurogen stockholders earlier today.
Through the alliance, Neurogen and Merck have generated a broad spectrum of chemical intellectual property and several leading drug candidates, including MK-2295.
Neurogen Corporation (Branford, CT; 203-315-4615), a leading small molecule drug discovery and development company, and Aventis Pharma (Bridgewater, NJ; 908-231-4659), jointly announced an exclusive worldwide collaboration to develop new drugs for treatment of depression, anxiety, and other stress-related disorders based on Neurogen's innovative portfolio of pre-clinical corticotrophin releasing factor (CRF1) antagonist compounds.
Neurogen Stockholders Meeting to be held December 23, 2009
31 /PRNewswire-FirstCall/ -- Neurogen Corporation , a drug discovery and development company, announced today that William H.
Under the new licensing agreement, Pfizer will develop GABA-based drug candidates identified by Neurogen to treat anxiety and dementia in companion animals.
Neurogen Corporation (NASDAQ: NRGN) announced today that it received a NASDAQ staff determination letter on December 11, 2009, notifying the company that it has not regained compliance, during a prescribed period, with NASDAQ Listing Rule 5450(a)(1), which requires the stock of listed companies to trade at or above $1.
30 /PRNewswire-FirstCall/ -- Neurogen Corporation today announced that it has commenced a Phase II clinical trial in chronic insomnia patients with the Company's insomnia agent, NG2-73.
Neurogen Corporation (NASDAQ: NRGN), a drug development company historically focused on drugs for psychiatric and neurological disorders, today announced financial and operating results for the quarter ended September 30, 2009.
26 /PRNewswire-FirstCall/ -- Neurogen Corporation , a drug discovery and development company, announced today that it will release its third quarter 2006 financial results on Friday, November 3, 2006 before the opening of the U.